Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today:ATI Inc. (ATI) is a specialty manufacturing company. The Zacks Consensus Estimate for its current year earnings has been revised 5.2% downward over the last 60 days.Akebia Therapeutics, Inc. (AKBA) is a biopharmaceutical company. The Zacks Consensus Estimate for its current year earnings has been revised 26.3% downward over the last 60 days.Alta Equipment Group Inc. (ALTG) is an equipment dealership company. The Zacks Consensus Estima ...

Chris Lau is an individual investor and economist with 30 years of experience covering life science, technology, and dividend-growth income stocks. He has degrees in Microbiology and Economics. Chris runs the investing group DIY Value Investing where he shares his top stock picks of undervalued stocks with catalysts for upside, dividend-income recommendations with quant and payment calendar tracking, high upside plays, and research requests to help you become a better do-it-yourself investor. Learn more. To ...

Akebia continues to publish important results of FO2CUS trial to further physicians' understanding of Vafseo® (vadadustat) CAMBRIDGE, Mass., Nov. 14, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the American Journal of Kidney Disease has published the results of FO2CUS, an open-label study evaluating the efficacy and safety of vadadustat, an oral hypoxia-inducible fa ...

Group 1 - Akebia Therapeutics, Inc. is a biopharmaceutical company focused on improving the lives of individuals affected by kidney disease [1][2] - The company will have its CEO, John Butler, present at the Jefferies London Healthcare Conference on November 21, 2024, at 1:00 PM GMT [1] - A webcast of the presentation will be available for 30 days on Akebia's website [1] Group 2 - The Jefferies London Healthcare Conference is scheduled to take place from November 19-21, 2024, in London [2] - Akebia Therapeutics was founded in 2007 and is headquartered in Cambridge, Massachusetts [2]

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q3 2024 Earnings Conference Call November 7, 2024 8:00 AM ET Company Participants Mercedes Carrasco - Senior Director, Investor Relations John Butler - Chief Executive Officer Nick Grund - Chief Commercial Officer Erik Ostrowski - Chief Financial and Business Officer Conference Call Participants Allison Bratzel - Piper Sandler Ed Arce - H.C. Wainwright Julian Harrison - BTIG Operator Good day and thank you for standing by. Welcome to the Akebia's Third Quarter 2024 Fi ...

Akebia Therapeutics (AKBA) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.08 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -100%. A quarter ago, it was expected that this kidney disease treatment developer would post a loss of $0.06 per share when it actually produced a loss of $0.04, delivering a surprise of 33.33%.Over the last four quar ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading symbol(s) Name of each exchange on which registered Common Stock, $0.00001 par value per share AKBA The Nasdaq Capital Market Emerging growth company ☐ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECT ...

Product Development and Market Launch - Vafseo® (vadadustat) is on track for U.S. market availability expected in January 2025[1] - Vafseo received TDAPA reimbursement approval, effective January 1, 2025, along with a Level II Healthcare Common Procedure Coding System code[4] - Akebia has partnered with U.S. Renal Care to initiate a trial evaluating mortality and hospitalization outcomes for dialysis patients taking Vafseo[2] - Akebia expects to enter into contracts with additional dialysis providers to increase coverage for Vafseo throughout 2024[25] - The company plans to establish Vafseo as the new oral standard of care for dialysis patients with anemia[25] Financial Performance - Total revenues for Q3 2024 were $37.4 million, down from $42.0 million in Q3 2023, with Auryxia® net product revenues at $35.6 million compared to $40.1 million[7] - Total revenues for Q3 2024 were $37,428,000, a decrease of 11.5% from $42,046,000 in Q3 2023[28] - Product revenue, net for Q3 2024 was $35,592,000, down from $40,118,000 in Q3 2023, reflecting a decline of 11.8%[28] - Net loss for Q3 2024 was $20.0 million, compared to $14.5 million in Q3 2023, including $4.4 million in non-cash interest expense[12] - Net loss for Q3 2024 was $20,039,000, compared to a net loss of $14,489,000 in Q3 2023, representing an increase in loss of 38.5%[28] Expenses and Cost Management - Cost of goods sold (COGS) decreased to $14.2 million in Q3 2024 from $18.0 million in Q3 2023, aided by a $3.7 million benefit from selling previously written-down inventory[9] - Research and development expenses were $8.5 million in Q3 2024, down from $13.3 million in Q3 2023, due to completed clinical trials and reduced costs[10] - Research and development expenses for Q3 2024 were $8,487,000, a decrease of 36.5% from $13,330,000 in Q3 2023[28] - Selling, general, and administrative expenses increased to $26.5 million in Q3 2024 from $22.7 million in Q3 2023, driven by preparatory activities for Vafseo[11] - Selling, general and administrative expenses increased to $26,516,000 in Q3 2024, up from $22,710,000 in Q3 2023, marking an increase of 16.4%[28] Cash Position - Cash and cash equivalents as of September 30, 2024, were approximately $34.0 million, expected to fund operations for at least two years[13] - Cash and cash equivalents as of September 30, 2024, were $34,019,000, down from $42,925,000 as of December 31, 2023[29] - Akebia's existing cash resources are expected to fund its current operating plan, including the U.S. Vafseo launch, for at least two years[25]

Vafseo® (vadadustat) on track for U.S. market availability expected in January 2025 Over 300,000 patients, representing approximately 60% of dialysis patient lives in the U.S., now covered under dialysis provider contracts for Vafseo Vafseo granted TDAPA reimbursement and issued a Level II Healthcare Common Procedure Coding System code Akebia to Host Conference Call at 8:00 a.m. ET on November 7CAMBRIDGE, Mass., Nov. 7, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical com ...

Akebia to Host Conference Call on November 7, 2024, at 8:00 a.m. ESTCAMBRIDGE, Mass., Nov. 1, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the third quarter ended September 30, 2024, on Thursday, November 7, 2024, prior to the open of financial markets.Akebia will host a conference call on Thursday, November 7, 2024, at 8:00 a.m. EST to discuss its financial results and recent business highlights. To access the call, please registe ...